T0	Participants 40 65	persistent genital warts.
T1	Participants 326 349	recurrent genital warts
T2	Participants 383 430	conducted independently in Australia and China.
T3	Participants 757 826	Of 33 protocol compliant Brisbane recipients of placebo immunotherapy
T4	Participants 1027 1096	Among 102 protocol compliant Brisbane recipients of VLP immunotherapy
T5	Participants 1350 1356	Â± 7%).
T6	Participants 1357 1417	Of 52 protocol compliant placebo immunotherapy recipients in
T7	Participants 1672 1764	observed for the 168 Wenzhou protocol compliant subjects who also received VLP immunotherapy
T8	Participants 1907 1990	of recurrent genital warts in patients for whom destructive therapy is unsuccessful